WITHDRAWN

The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

NCT01914211•Aymen N Naguib

Summary

This is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All neonates undergoing arterial switch or aortic arch procedure utilizing cardiopulmonary bypass (CPB).

Exclusion Criteria

•Jehovah's witness patients.

Locations (1)

Nationwide Children's Hospital

Columbus, Ohio, United States

Key Dates

Start Date

July 1, 2013

Primary Completion Date

June 1, 2014

Completion Date

June 1, 2014

Last Updated

February 1, 2017

Conditions

Congenital Heart Disease

Interventions

Tranexamic Acid

DRUG

Acute Normovolemic Hemodilution

PROCEDURE

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213

Univentricular HeartCongenital Heart Disease+2 more

View study

RECRUITINGNA

Aim 3: Pilot Study of a Serious Game to Promote Transition Readiness Skills

NCT07042334

Serious GamesTransition-age Youth+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 1, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITING